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BACKGROUND: The G-protein-coupled formylpeptide receptor (FPR) that mediates chemotaxis of phagocytic leucocytes induced by
bacterial and host-derived chemotactic peptides is selectively expressed by highly malignant human gliomas and contributes to
tumour growth and angiogenesis. As invasion of surrounding normal tissues is one of the important features of tumour malignancy,
we investigated the function of FPR in the invasive behaviour of human glioblastoma cells.
METHODS: Cells (FPR
þ and FPR
 ) were isolated by single-cell cloning from a human glioblastoma cell line U-87MG. The FPR
expression was assayed by flow cytometry and reverse transcription PCR. The function of FPR was investigated by chemotaxis and
calcium flux induced by FPR agonist fMLF. Tumour cell motility was assayed by a wound-healing model in vitro. The growth and
invasive phenotype were observed with subcutaneous implantation of tumour cells in nude mice. Over-expression of FPR in FPR
 
cells was performed by transfection of a plasmid vector-containing human FPR gene.
RESULTS: One of the glioma clones F9 that expressed high level of FPR showed a more ‘motile’ phenotype in vitro as compared with a
clone G3 without FPR expression. Although F9 and G3 clones both formed subcutaneous tumours in nude mice, only F9 tumours
invaded surrounding mouse connective tissues. Over-expression of FPR in G3 clone (G3F) increased the cell motility in vitro and the
capacity of the cells to form more rapidly growing and invasive tumours in nude mice. We further found that, in addition to
supernatant of necrotic tumour cells, foetal calf serum and human serum used in culture media contained FPR agonist activity and
increased the motility of FPR-expressing glioblastoma cells.
CONCLUSION: The expression of FPR is responsible for increased motility of human glioblastoma cells and their formation of highly
invasive tumours.
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Malignant gliomas are diffuse, often multifocal and invasive
tumours with a dismal prognosis. A major barrier to effective
treatment of malignant gliomas is their tendency to extend tendrils
of tumour away from the main tumour mass. In fact, 95% gliomas
recur within 2.5cm of the resection margin, which contains
residual tumour cells that act as a ‘disease reservoir’ (Giese et al,
2003). Malignant glioma cells acquire characteristic properties
from a number of coordinated cellular programmes, including
abberant expression of cell surface chemoattractant and growth-
factor receptors, necessary for increased proliferation (e.g.
expansion), migration (e.g. motility), invasion (e.g. extracellular
matrix (ECM) degradation) (Demuth and Berens, 2004) and
angiogenesis (e.g. production of angiogenic factors) (Giese et al,
2003).
Formylpeptide receptor (FPR) is a G-protein-coupled receptor
(GPCR), originally identified in phagocytic leucocytes, that
mediates cell chemotaxis and activation in response to the
bacterial formylated chemotactic peptides (e.g. fMLF). Agonist
binding to FPR elicits a signal transduction cascade involving
phosphatidylinositol 3-kinase, protein kinase C (PKC), mitogen-
activated protein kinases (MAPKs) and the transcription-factor
nuclear-factor (NF)-kB( L eet al, 2002; Cheng et al, 2007). Owing to
its expression in cells of the immune system and its interaction
with bacterial chemotactic peptides, FPR was thought to partici-
pate in host defence against microbial infection. In support of this
notion, mice depleted of the FPR analogue mFPR1 were more
susceptible to infection by Listeria monocytogenes (Gao et al, 1999)
that produced high affinity mFPR1 agonist peptides (Southgate
et al, 2008). Recently, a number of host-derived chemotactic
agonists of FPR have been identified, including formylpeptides
potentially released by mitochondria of ruptured cells (Rabiet et al,
Received 16 November 2009; revised 25 January 2010; accepted 1
February 2010; published online 2 March 2010
*Correspondence: Dr J Huang, College of High Altitude Military
Medicine, Third Military Medical University, Chongqing 400038, P. R.
China; E-mail: hj3red@gmail.com or
JM Wang, Laboratory of Molecular Immunoregulation, Cancer and
Inflammation Program, Center for Cancer Research, National Cancer
Institute at Frederick, Building 560, Room 31-76, Frederick, MD 21702,
USA; E-mail: wangji@mail.nih.gov
British Journal of Cancer (2010) 102, 1052–1060
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s2005), annexin I produced by activated epithelia (Xia et al, 2002)
and a neutrophil granule protein, cathepsin G (Sun et al, 2004). In
addition, functional FPR has been detected in cells of nonhaemato-
poietic origin, such as lung epithelial cells (Rescher et al, 2002) and
hepatocytes (McCoy et al, 1995). These findings expanded the
spectrum of pathophysiologic processes in which FPR may have a
function.
As a support of the function for FPR in diseases other than anti-
microbial host defence, our recent studies revealed that tumour
cells of a majority of highly malignant human gliomas, including
anaplastic astrocytoma (grade III) and glioblastoma multiforme
(GBM, grade IV), express FPR (Zhou et al, 2005; Huang et al,
2008a). The FPR expressed in tumour cells derived from human
GBM by responding to cognate agonist peptide fMLF and
agonist(s) released by necrotic tumour cells promote the direc-
tional migration, survival and production of angiogenic factors by
tumour cells (Zhou et al, 2005; Yao et al, 2008a). Depletion of FPR
by short-interference RNA markedly reduced the tumourigenicity
of GBM cells in immune-deficient mice (Zhou et al, 2005). Thus,
both in vitro and in vivo evidence supports the potential for FPR to
exacerbate the progression of highly malignant human glioma. As
malignant tumours are composed of heterogeneous cells varying in
their degree of differentiation or malignancy, and as increased
motility and invasiveness define more highly malignant tumour
cell subsets, we studied the contribution of FPR to the invasive
capacity of human GBM cells. Here, we report that expression of
FPR is sufficient to endow GBM cells with a more motile
phenotype and with greater capacity to form tumours infiltrating
surrounding normal tissues.
MATERIALS AND METHODS
Cells and reagents
Human GBM cell line U-87MG was obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). The cells
were grown in Dulbecco’s modified Eagle medium (DMEM)
containing 10% foetal calf serum (FCS) and antibiotics; fMLF
was purchased from Sigma-Aldrich (St Louis, MO, USA).
Antibodies against phosphorylated Akt, Akt, phosphorylated p38,
p38, phosphorylated Erk, Erk, phosphorylated EGFR (tyrosine 992)
and EGFR were from Cell Signaling Technology (Beverly, MA,
USA). Antibodies against vimentin, glial fibrillary acidic protein
(GFAP) and FPR were from BD Biosciences (San Jose, CA, USA).
Isolation of FPR-positive and -negative tumour cell clones
U-87MG cells were plated in 96-well plates at a concentration of a
single cell per well. Wells containing either none or more than one
cell were excluded for further analysis. After expansion of
single-cell clones, the FPR
þ and FPR
  subclones were identified
by immunofluorescence staining of FPR, reverse transcription PCR
(RT–PCR) and functional assays. One cell clone expressing high
level of FPR was designated F9, whereas one clone, which was
completely negative for FPR expression, was termed as G3.
Over-expression of FPR in G3 cells
G3 cells were transfected with the Superfect Transfection Reagent
(QIAGEN, Valencia, CA, USA) and 5mg FPR-expressing plasmid
pcDNA3 or blank plasmid pcDNA3 (Invitrogen, Carlsbad, CA,
USA). The FPR-transfected cells (G3F) and mock-transfected
cells (G3M) were selected and maintained by incubation with
800mgml
–1 antibiotic G418. G3F cells were selected by flow
cytometry sorting after staining with a PE-conjugated monoclonal
antibody against FPR.
Chemotaxis, Ca
2þ flux and immunoblotting
Assays for tumour cell chemotaxis (Le et al,2 0 0 0 ;Z h o uet al, 2005),
Ca
2þ mobilisation and immunoblotting were performed according
to the described procedures (Le et al, 2000; Zhou et al,2 0 0 5 ) .
Wound-healing assays
The wound-healing assays were performed according to the
published procedures (Liang et al, 2007). Briefly, tumour cells
were labelled either by CellTracker Red CMPTX or CellTracker
Green CMFDA (Invitrogen). Equal number of labelled cells were
mixed and planted in 6cm culture dishes. When the cells reached
confluence, a 1000ml pipette tip (ThermoFisher Scientific,
Waltham, MA, USA) was used to scratch and create a gap in the
monolayer. Detached tumour cells were immediately removed by
replacement of culture medium. The cell movement phase images
were subsequently captured under light microscopy. The fluores-
cence time-lapse images were monitored by laser confocal
microscopy. The results were quantified by calculating mean
migrated distance of leading cells or the cell number filled in the
scratched area (gate).
Adhesion assays
Flat-bottomed 96-well plates were coated with 0.5% gelatin or
30mgml
–1 laminin at room temperature for 1h followed by 1%
heat-inactivated BSA for 30min at room temperature. The plates
were washed twice by PBS, and 100mlo f4  10
5 per ml tumour
cells were added to the wells. The plates were cultured for 10min at
371C and non-adherent cells were then removed by washing with
ice-cold PBS. The number of adhering cells was evaluated by MTT
method according to the kit manual (Sigma-Aldrich). The
percentage of adhered cells in total input cells was calculated as
the rate of adhesion.
Zymography for MMP expression
Zymography (gelatin-substrate gel electrophoresis) was performed
according to the described methods (Zhou et al, 2002) and the
manual of the Zymography system (Invitrogen).
Vascular endothelial growth factor production and
microvascular density
Vascular endothelial growth factor (VEGF) in the supernatants of
tumour cells was quantified by commercial enzyme-linked
immunosorbent assay kits (Lymphokine Testing Laboratory, SAIC
Frederick, Frederick, MD, USA). Frozen sections of xenograft
tumours were stained with anti-human VEGF and PE-labelled
second antibodies to visualise the VEGF expression, with anti-
CD105 antibodies (Biolegend, San Diego, CA, USA) and immuno-
chemical staining kit (LabVision, Fremont, CA, USA) to visualise
the microvasculature.
Flow cytometry, RT–PCR, immunocytochemistry
tumourigenesis, histology, cell proliferation and tumour
colony formation
Flow cytometry, RT–PCR, immunocytochemistry tumourigenesis,
histology, cell proliferation and tumour colony formation were
performed as reported earlier (Huang et al, 2007, 2008b).
Statistical analyses
All experiments were performed at least three times and
representative results are shown. A computer-aided Mann–
Whitney U-test program SPSS (Version 11.0) (GraphPad Software
Inc., San Diego, CA, USA) was used to determine the statistical
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ssignificance of the differences between cell responses to testing
materials and controls in experiments of chemotaxis, cell prolifera-
tion, adhesion, tumour colony formation and growth in nude mice.
RESULTS
Isolation of FPR-positive and -negative subsets from
U-87MG cells
Despite the high proportion of FPR-expressing cells in U-87MG cell
line, it also contained subsets that were negative for FPR. By single-
cell cloning, we isolated an F9 subclone that expressed high level of
FPR at both protein and mRNA levels. In contrast, a G3 subclone
was entirely negative for FPR (Figure 1A and B). Functionally, the
FPR agonist fMLF induced robust chemotaxis and calcium flux
responses in F9 cells, but not in G3 cells (Figure 1C). As reported
(Zhou et al, 2005; Huang et al, 2007), fMLF also induced the
phosphorylation of MAPKs, Akt and EGFR in F9, but not G3, cells
(Figure 1D). After at least 15 passages, both F9 and G3 cells
maintained their FPR-positive and -negative states, respectively.
Phenotype of FPR
þ and FPR
  subclones
Both F9 and G3 subclones expressed vimentin, a marker for
astroglial cell precursors, with lower levels in the FPR
  G3 cell
subclone. As compared with F9 cells, G3 cells expressed a higher
level of GFAP, a glial differentiation maker (Figure 2A), suggesting
that although both subclones were from a GBM cell line, the FPR
þ
clone F9 was more poorly differentiated as compared with the
FPR
  clone G3.
We next compared the mobility of FPR
þ F9 and FPR
  G3 cells in
a wound-healing model by creating a gap in a confluent cell
monolayer. We found that the FPR
þ F9 cells moved more rapidly
than the FPR
  G3 cells to fill the gap in the cell monolayer
(Figure 2B). In nude mice, although both subclones formed
tumours, only the FPR
þ F9 tumours invaded the surrounding
mouse connective tissues with disruption of the dermis. In contrast,
tumours formed by G3 cells were encapsulated by intact fibrous
membrane without apparent invasion of normal mouse tissues by
tumour (Figure 2C). These results indicate that in a heterogeneous
human GBM cell line, the FPR
þ cells exhibit a more motile and
invasive behaviour as compared with FPR
  counterpart cells.
Enhanced FPR
þ cell motility and adhesion in vitro
To more precisely study the contribution of FPR to tumour cell
motility and invasiveness, we transfected FPR into FPR
  G3 cells.
Flow cytometry confirmed FPR expression in transfected G3 cells
(G3F), but not in mock-transfected G3 cells (G3M) (Supplementary
Figure 1A). Functionally, FPR agonist fMLF induced chemotaxis,
calcium flux (Supplementary Figure 1B) and phosphorylation of
Erk1/2 and p38 MAPKs as well as Akt in G3F cells (Supplementary
Figure 1C). Stimulation of FPR in G3F cells also transactivated
EGFR by inducing phosphorylation of the tyrosine residue 992
(Supplementary Figure 1C). Thus, transfection of FPR in an
FPR
  subclone of GBM line enabled these cells to exhibit full
agonist-induced responses as shown by tumour cells constitutively
expressing FPR (Zhou et al, 2005; Huang et al, 2007).
We then measured the motility of G3F and G3M cells in the
wound-healing model in vitro. As shown in Figure 3A and B, G3F
cells labelled with green fluorescence showed more rapid locomo-
tion than G3M cells towards the centre of the gap created on cell
monolayer in the presence of 100nM fMLF or 10% human serum
(HS). A time-lapse imaging of the migration in the ‘wound’ of G3F
and G3M cells in medium with 10% HS is shown in Supplementary
Movie 1. In addition, G3F and F9 cells cultured in 100nM fMLF
and 10% HS showed increased adhesion on gelatin- and laminin-
coated plastic than their respective control G3M and G3 cells
(Figure 3C). These results confirm that FPR expression enables
GBM cells to exhibit higher level of motility and adhesion in the
presence of FPR agonist fMLF or HS.
MMP production and growth of G3F cells in vitro
As increased production of MMP2 and MMP9 is associated with
tumour invasion, we examined the capacity of G3F cells to produce
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Figure 1 The FPR expression and function in FPR
þ and FPR
  subclones from human U-87MG glioblastoma cells. Clones (FPR
þ (F9) and FPR
  (G3))
were isolated by single-cell clone. (A) FACS analysis of FPR expression on tumour cells. The FPR expression was measured by a PE-conjugated mouse
monoclonal antibody against FPR. %¼percentage of FPR-positive cells; MFI¼mean fluorescence intensity. (B) The expression of FPR mRNA. The levels of
FPR mRNA were examined by RT–PCR. GAPDH was used as control. (C) The fMLF-induced chemotaxis and Ca
2þ flux. Cell chemotaxis was assayed in
response to fMLF. The results are expressed as the mean migrated cell number (±s.e.) in three high-powered fields of three independent experiments.
*Indicates significantly increased cell migration as compared with medium control (0) (Po0.01). The fMLF-induced Ca
2þ flux was measured in a
fluorescence spectrometer. The FPR agonist peptide fMLF-induced fluorescence intensity in F9 and G3 cells was expressed as the ratio at wavelength 340
out of 380 calculated by an FLWINLab program. (D) FPR-mediated activation of signal transduction molecules. Lysates of F9 (FPR
þ) and G3 (FPR
 ) cells
stimulated with 100nM fMLF for 10min were examined for phosphorylated ERK1/2, p38 and EGFR (Tyr992) by western blotting. Total ERK1/2, p38 and
EGFR were used as controls.
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sthe enzymes that are implicated in the breakdown of basement
membrane by invading tumour cells. As shown in Figure 4A, the
mRNA levels of MMP2 and MMP9 in G3F cells were increased
when the cells were stimulated with the FPR agonist or cultured in
the presence of HS. Zymography of conditioned media revealed
that the levels of soluble pro-MMP-2 protein from G3F cells were
higher than G3M cells (Figure 4B). In addition, fMLF increased the
level of pro-MMP2 released by G3F cells. Moreover, the active
MMP2 produced by G3F cells was at a higher level than that
produced by G3M cells despite the absence of fMLF or HS in cell
culture. We further found that G3 cells over-expressing FPR (G3F)
grew more rapidly (Figure 4C) and they formed more large-size
tumour colonies in soft agar (Figure 4D) as compared with mock-
transfected cells G3M.
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*Significantly slower locomotion of G3 cells (Po0.01) as compared with F9 cells. (C) Invasiveness of xenograft tumours. F9 and G3 cells at 5 10
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100ml PBS per mouse were injected subcutaneously into the flanks of athymic mice. After 30 days, the xenograft tumours were sectioned and stained by HE.
Arrows indicate F9 tumour intruding mouse dermis and well-encircled G3 tumour.
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Figure 3 The GBM cell motility and adhesion in vitro.( A, B) Cell motility. The motility of CMPTX-labelled G3M (red) and CMFDA-labelled G3F (green)
in wound-healing model were assayed in the presence of 100nM fMLF or 10% HS by time-lapse photographing under confocal microscope (A). The cell
number in a rectangle gate was counted after 4, 8 and 16h (B). *Indicates significant increased cell number of G3F cells as compared with G3M cells and
media (Po0.05). (C) Adhesion. Serum-starved F9, G3, GM and G3F cells were cultured on 0.5% gelatin and 30mgml
–1 laminin-coated culture plates at
371C for 30min followed by washing with ice-cold PBS. The adhesion rate was the percentage of adhered cells in total input cells. *Indicates significantly
increased adhesion of FPR-expressing cells (F9 and G3F) as compared with G3M cells (Po0.05). Significantly increased cell adhesion as compared with cells
treated with medium alone (Media) (Po0.05).
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in tumours formed by G3F cells
On the basis of in vitro findings that over-expression of FPR in
G3 GBM subset cells transformed the cells into a more invasive
and proliferative phenotype, we injected the tumour cells
subcutaneously into the flanks of athymic mice and measured
the rate of tumourigenesis. Tumours formed by G3F cells grew
more rapidly than those formed by the wild-type or mock-
transfected G3 cells (Figure 5A). Histological examination showed
tumours formed by G3F cells penetrated the dermis and invaded
the surrounding mouse connective tissues. In contrast, G3M
tumours grew more slowly and were surrounded by intact dermis
(Figure 5B).
We then measured VEGF production by U-87MG subclones
in vitro and the density of microvessles in xenograft tumours.
Stimulation of G3F, F9 cells and the parental U-87MG cells with the
FPR agonist fMLF increased their production of VEGF (Figure 5C).
The increased production of VEGF by FPR-expressing G3F cells
in vitro was corroborated by significantly increased VEGF
production and the microvessels in tumours formed by these cells
as shown in Figure 5D. Thus, FPR expression is sufficient to
promote the growth, invasion and angiogenesis of tumour cells,
which were originally FPR negative and had a lesser degree of
malignancy.
Identification of potentially endogenous source of FPR
agonist activity
We earlier observed that the supernatants of necrotic U-87MG cells
and xenograft tumour tissues of glioma cells contained FPR
agonist activity (Zhou et al, 2005), thus may represent an
endogenous source of FPR ligands in the tumour microenviron-
ment. As FPR
þ GBM cell clones exhibited increased motility
in vitro in serum-containing media without the addition of
exogenous FPR agonists, we examined the possibility of the
presence of FPR agonists in culture media. We found that both
FCS and HS were able to induce migration of GBM cell subsets
in vitro and the FPR-expressing F9 and G3F cells showed higher
levels of cell migration in response to serum-containing media
as compared with the G3 and G3M counterparts, respectively
(Figure 6A–C). The tumour cell migration inducing activity of FCS
or HP was composed mainly of chemotactic with minor, but
significant contribution of the chemokinetic element as measured
by checkerboard analyses (Supplementary Table 1) in which
tumour cells also migrated in the presence of negative serum
gradients or equal serum concentrations in both upper and lower
wells of the chemotaxis chambers. Importantly, the migration of
FPR
þ tumour cells induced by FCS or HS was partially and
significantly inhibited by an FPR-specific antagonist cyclosporine
H (CsH) (Wenzel-Seifert and Seifert, 1993; De Paulis et al,
1996), which had no effect on EGF-induced tumour cell migration
(Figure 6B and C), suggesting the presence of FPR agonist(s) in
FCS and HS. The HS also induced a robust intracellular Ca
2þ
mobilisation in G3F cells (Figure 6D) and attenuated the
subsequent cell response to fMLF (Figure 6D). Conversely, fMLF
also significantly desensitised HS-induced Ca
2þ mobilisation in
G3F cells (Figure 6D). These results indicate the presence of FPR
agonists in FCS and HS and provide a basis for the increased
motility of FPR
þ tumour cells in the absence of the defined FPR
agonists fMLF. Thus, tumour cells may take advantage of the
presence of FPR agonists in both necrotic tumour supernatants
and in normal serum to promote their growth, invasion and
angiogenesis.
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Figure 4 The MMP expression and cell growth in vitro.( A) Expression of MMP2 and MMP9. G3F cells were cultured in the presence or absence of fMLF
or 10% HS for 24h at 371C, followed by RT–PCR detection of mRNA for MMP2 and MMP9. (B) Zymogram. G3M and G3F cells were cultured in the
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zymography. (C) Growth of FPR-transfected cells in culture. The FPR-transfected G3F or mock G3M cells were cultured in 0.5% FCS/DMEM containing 10%
AlamarBlue with or without 1mM fMLF. Cell growth was monitored by measuring the absorbance at 570 and 600nm. The results are presented as the mean
of ‘growth index’ (±s.e., n¼6).
#Indicates significantly increased growth of G3F cells as compared with G3M cells (Po0.05) and *indicates significantly
increased growth of G3F cells in the presence of fMLF as compared with growth in the absence of fMLF (Po0.05). (D) Colony formation in soft agar.
Tumour cells suspended in 200ml 0.3% agar (2500 cells) were layered on solidified bottom agar in the wells of 24-well plates. The cells were grown in
DMEM containing 10% FCS at 371C. After 3 weeks, tumour colonies were photographed under light microscopy. The results are expressed as the mean
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Human gliomas are heterogeneous in their degree of malignancy,
ranging from more slowly growing astrocytoma to fast growing
and highly invasive GBM. This study showed that even in a well-
established GBM cell line, FPR is expressed at different levels by
cell subsets, and an FPR-expressing subset is more motile and
forms more rapidly growing invasive tumours in nude mice as
compared with its FPR-negative counterpart. The FPR-expressing
clone F9 also expressed higher levels of vimentin, an astroglia
precursor marker, but lower levels of the differentiation marker
GFAP than the FPR-negative subset G3. This is consistent with the
findings with surgically removed human glioma specimens, in
which FPR expression is associated with poorly differentiated
tumours, and within individual human gliomas, tumour cells
frequently exhibit remarkable heterogeneity (Zhou et al, 2005).
This may explain our findings that 3 out of 14 anaplastic
astrocytoma were negative for FPR and 2 out of 13 of less invasive
astrocytoma are positive for FPR (Zhou et al, 2005). The presence
of highly proliferative and invasive cell populations in a given solid
tumour determines the rate of tumour progression and the
lethality to the host. The U87 glioblastoma cell line contains both
FPR
þ and FPR
  subpopulations: although the FPR
þ subpopula-
tion represented by F9 clone, the G3 subclone is FPR
  as reported
in this study. However, both the FPR
þ F9 subclone and the FPR
 
G3 subclone express EGF receptor and proliferate in response to
EGF. Therefore, in the heterogeneous U87 cell line, the FPR
þ cells
did not show apparent growth advantage over FPR
  cells in vitro.
This may explain why FPR
  cells may sustain their growth over
longitudinal passaging and are uncoverable in the heterogeneous
population. The FPR gene has a single copy in FPR
þ U87 cells.
Over a period of 15 passages, these FPR
þ cells represented by the
F9 clone maintained the same level of FPR expression. However, it
is interesting to note that it has been reported that glioma stem-
like cells isolated from U87 cell line and primary human gliomas
express FPR (Yao et al, 2008b) and such stem-like cells
differentiate in vitro to yield both FPR
þ and FPR
  descendents.
Therefore, it seems that FPR
þ malignant glioma cells may
represent a more poorly differentiated cell population with higher
degree of malignancy.
One of the most important features of malignant tumour cells is
their capacity to break the barrier of surrounding normal host tissues.
This invasion process is known to depend not only on tumour cell
motility, but also on tumour cell-secreted MMPs to degrade ECM.
The MMPs also cleave and activate other growth factors such as
TGF-b that are implicated in GBM motility and proliferation.
The expression of MMPs in tumour cells is induced by
cytokines, growth factors, tumour promoters, physical stress,
oncogenic transformation, and cell–matrix and cell–cell inter-
actions. Several MMP genes are inducible by extracellular stimuli,
which activate the AP1 transcription-factor complex through
pathways involving MAPKs (ERK1/22, JNKs and p38) and PKC;
PKC is also known to have a function in increasing MMP9
expression by malignant glioma cells (Yabkowitz et al, 1999)
through cytoskeletal changes and NF-kB (Chintala et al, 1998).
Activation of FPR in myeloid and GBM cells triggers these
signalling events (Zhou et al, 2005; Kam et al, 2007); therefore,
provide mechanistic basis for its ability to regulate the production
and activation of MMPs. The capacity to mediate MMP production
may be a common feature for chemoattractant GPCRs. For
instance, an FPR variant receptor, FPRL1, in monocytic cells
(Lee et al, 2005) and a chemokine GPCR CXCR3 in colon cancer
cells have also been shown to up-regulate MMP9 (Zipin-Roitman
et al, 2007). Thus, GPCRs have an important function in increasing
the proteolytic processes favouring leucocyte infiltration of tissues
and tumour dissemination.
Progression of malignant tumours depends on timely neovas-
cularisation in tumour and surrounding tissues. One of the most
potent angiogenic factors produced in solid tumours is VEGF,
which not only acts on vascular endothelial cells, but also increases
the survival, migration and invasion of many tumour cells bearing
VEGF receptors. In addition, VEGF is a potent suppressor of
antigen-presenting cells in tumour microenviroment, contributing
to the establishment of immune privilege of tumours. Malignant
gliomas, notably GBMs, are characterised by vigorous angiogenesis
and the production of copious amounts of VEGF. Our earlier study
showed that stimulation of FPR in human GBM cells increased cell
production of VEGF (Zhou et al, 2005) and another angiogenic
chemokine IL8 (CXCL8) (Yao et al, 2008a). This study indicates
that expression of FPR alone in originally FPR-negative tumour
cells is sufficient for tumour cells to produce VEGF in conventional
culture conditions in the presence of FCS or HS, and stimulation
with FPR agonist peptide fMLF further increased VEGF produc-
tion. The more vigorous angiogenesis by FPR
þ GBM cells was
further shown by higher microvessel density in tumours formed by
such tumour cells, indicating a pivotal function of FPR in
enhancing the angiogenic and vasculogenic process in GBM. It is
interesting to note that MMPs have been reported to also act as
‘angiogenic switch’ in tumour neovascularisation (Bergers et al,
2000). Thus, FPR may promote GBM angiogenesis through direct
induction of angiogenic factors and through elevated MMPs in
tumour microenvironment.
Our study showing FPR agonist activity in the serum and
supernatants of necrotic tumour cells (Zhou et al, 2005) strongly
suggests that this receptor expressed by GBM cells may interact
with host-derived agonists in vivo. Although the precise chemical
nature of FPR agonist(s) contained in serum and necrotic
tumour supernatants remains to be clarified, our preliminary
results suggest that the FPR agonists are of small molecule peptide
nature (Zhou et al, 2005). Plasma is the most complex
human-derived proteome known to contain proteins derived
from blood cells and other tissues including those released
by normal or damaged cells and aberrant proteins from tumour
cells. As proteins in the circulatory system are exposed to a variety
of proteases and peptidases, plasma is rich in peptides of various
size to constitute ‘peptidome’. In this context, some endogeneous
agonists of FPR and its variant receptors have been identified,
such as the neutrophil granule protein cathepsin G (Sun et al,
2004), cleaved peptide from urokinase plasminogen activator
receptor (Resnati et al, 2002), a fragment of heme-binding proteins
(F2L) (Migeotte et al, 2005) and formylated peptides from
mitochondria (Rabiet et al, 2005). In addition, a phospholipid-
binding protein annexin I, which was reported to be a ligand
for FPR and its variant receptors, has been implicated in
promoting the invasiveness of a human intestinal cancer cell line
and a mouse melanoma cell line (Babbin et al, 2006; Rondepierre
et al, 2009). Although the molecular nature of the FPR-stimulating
activity in sera remains to be elucidated, our further studies
showed that the chemotactic activity and colony-stimulating
activity contained in the supernatant of necrotic GBM cells
were depleted by immunoabsorption with an antibody against
annexin I (Yang et al, manuscript in preparation), suggesting that
annexin I is likely a major component responsible for the FPR-
stimulating activity released by necrotic GBM cells. Thus,
identification and characterisation of FPR agonist(s) in human
GBM tissues, which may activate the receptor on tumour cells will
shed light on the mechanisms of tumour–microenvironment
interaction.
In summary, malignant tumours exploit their microenviron-
ment to favour their survival, growth, invasion of fertile ‘soil’,
and angiogenesis by ‘hijacking’ receptors involved in physiological
processes to sense agonists present in the intercellular milieu.
The FPR behaves as an oncoprotein that confers a highly
malignant phenotype on GBM cells with increased cell motility,
adhesion and release of proteases and production of angiogenic
factors. Our recent study (Huang et al, 2008b) found that the
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closely associated with increased methylation of the p53 tumour
suppressor gene promoter that reduced the capacity of p53 to
repress the active transcription of FPR gene. Consequently,
treatment of FPR-expressing GBM cells with methyltransferase
inhibitor or transfection of the wild-type p53 reduced FPR
expression and promoted GBM cell differentiation. Thus, studies
of the regulation and signal transduction of FPR in GBM may yield
novel molecular targets for anti-glioma therapy.
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